Hiroki A. Ueyama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hiroki A. Ueyama has a total of 176 co-authors. Here are the top co-authors by number of shared publications:
- Toshiki Kuno
Harvard Medical School
20 shared publications - Hisato Takagi
Shizuoka medical center, Shizuoka, Japan
12 shared publications Yosuke Hari
Shizuoka Medical Center, Shizuoka, Japan; Kitasato University School of Medicine, Sagamihara, Japan
7 shared publications- Takuya Matsushiro
Department of Cardiovascular Surgery, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan
6 shared publications - Tomo Ando
New York Presbyterian Hospital/Columbia University Medical Center, New York, NY, USA
6 shared publications - Yujiro Yokoyama
Department of Surgery St. Luke's University Health Network Fountain Hill Pennsylvania USA
6 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- p. e052355
Percutaneous Coronary Intervention in Dialysis Patients: Insights from a Nationwide Registry Analysis
Background: Trans‐radial intervention (TRI) has become the standard of care for percutaneous coronary intervention (PCI). However, in patients on dialysis, trans‐femoral intervention (TFI) remains predominant to preserve upper‐limb vessels for arteriovenous fistula despite heightened hemorrhagic risk. This study aimed to compare TRI and TFI in dialysis patients undergoing PCI. Methods: We used the National Cardiovascular Data Registry CathPCI Registry to compare patients on dialysis who underwent PCIs with TRI versus TFI from January 2018 to June 2025. An instrumental variable analysis with the institutional proportion of TRI use was performed to assess the risk of access‐site bleeding and other peri‐procedural outcomes. Results: Among 137,702 dialysis patients who underwent PCI, 28.3% of patients underwent TRI (n=38,901), while 71.7% patients underwent TFI (n=98,801). TRI was associated with a lower risk of bleeding at the access site (adjusted risk difference [aRD]: ‐0.35%; 95% confidence interval [CI]: ‐0.56% to ‐0.15%). Overall bleeding (aRD: ‐1.38%; 95% CI: ‐1.89% to ‐0.87%), access‐site hematoma (aRD: ‐0.86%; 95% CI: ‐1.13% to ‐0.60%), myocardial infarction (aRD: ‐0.21%; 95% CI: ‐0.39% to ‐0.03%), and mortality (aRD: ‐1.07%; 95% CI: ‐1.64% to ‐0.51%) were also less frequently observed in TRI. Conversely, TRI was associated with a higher risk of stroke (aRD: 0.23%; 95% CI: 0.001% to 0.45%), driven primarily by ischemic stroke. Conclusions: TRI was associated with a lower risk of bleeding events, but the effect size was modest. The higher observed stroke risk highlights a potential ischemic trade‐off and warrants further study.
- 10 November 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- p. e052355
Open AccessPercutaneous Coronary Intervention in Dialysis Patients: Insights from a Nationwide Registry Analysis
Background: Trans‐radial intervention (TRI) has become the standard of care for percutaneous coronary intervention (PCI). However, in patients on dialysis, trans‐femoral intervention (TFI) remains predominant to preserve upper‐limb vessels for arteriovenous fistula despite heightened hemorrhagic risk. This study aimed to compare TRI and TFI in dialysis patients undergoing PCI. Methods: We used the National Cardiovascular Data Registry CathPCI Registry to compare patients on dialysis who underwent PCIs with TRI versus TFI from January 2018 to June 2025. An instrumental variable analysis with the institutional proportion of TRI use was performed to assess the risk of access‐site bleeding and other peri‐procedural outcomes. Results: Among 137,702 dialysis patients who underwent PCI, 28.3% of patients underwent TRI (n=38,901), while 71.7% patients underwent TFI (n=98,801). TRI was associated with a lower risk of bleeding at the access site (adjusted risk difference [aRD]: ‐0.35%; 95% confidence interval [CI]: ‐0.56% to ‐0.15%). Overall bleeding (aRD: ‐1.38%; 95% CI: ‐1.89% to ‐0.87%), access‐site hematoma (aRD: ‐0.86%; 95% CI: ‐1.13% to ‐0.60%), myocardial infarction (aRD: ‐0.21%; 95% CI: ‐0.39% to ‐0.03%), and mortality (aRD: ‐1.07%; 95% CI: ‐1.64% to ‐0.51%) were also less frequently observed in TRI. Conversely, TRI was associated with a higher risk of stroke (aRD: 0.23%; 95% CI: 0.001% to 0.45%), driven primarily by ischemic stroke. Conclusions: TRI was associated with a lower risk of bleeding events, but the effect size was modest. The higher observed stroke risk highlights a potential ischemic trade‐off and warrants further study.
- 27 July 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (14) , 1927-1939
Trends and Outcomes of Antithrombotic Strategies for Valve-in-Valve TAVR
- 27 July 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (14) , 1927-1939
Trends and Outcomes of Antithrombotic Strategies for Valve-in-Valve TAVR
- 21 July 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (14) , e049636
Comparison of Outcomes of Leadless Versus Transvenous Pacemakers Following Tricuspid Valve Surgery
Background: Transvenous pacemaker implantation after tricuspid valve surgery may cause adverse outcomes due to lead–valve interactions. Although leadless pacemakers may mitigate these risks, empirical data remain limited. Methods: We compared outcomes of leadless versus transvenous pacemakers following tricuspid surgery using a target trial emulation framework. We analyzed Medicare beneficiaries aged ≥65 years who underwent tricuspid valve surgery and received a pacemaker during the index admission between 2017 and 2021, using propensity score matching weight analysis to control for confounders. Primary outcomes were in‐hospital death and 2‐year heart failure hospitalization. Secondary outcomes included 2‐year death. Results: We included 185 and 1336 patients in the leadless and transvenous groups, respectively. Use of leadless pacemakers increased from 6.3% in 2017 to 17.5% in 2021. Leadless pacemaker recipients more often underwent tricuspid valve replacement (29.2% versus 8.5%) while concomitant mitral surgery was less common (69.2% versus 86.8%). After adjustment, we found no evidence that in‐hospital death (adjusted odds ratio, 1.82 [95% CI, 0.65–5.13] for leadless) and 2‐year heart failure hospitalizations (subdistribution hazard ratio [HR], 0.88 [95% CI, 0.60–1.30] for leadless) differed between the 2 groups. We also found no evidence that 2‐year death (adjusted HR, 1.04 [95% CI, 0.69–1.57] for leadless) differed between groups. Conclusions: No statistically significant differences were detected between leadless versus transvenous pacemaker implantations after tricuspid valve surgery. However, CIs were wide, and a clinically meaningful difference in either direction cannot be excluded. The study may therefore be underpowered, and the absence of echocardiographic data limits assessment of tricuspid regurgitation, warranting prospective studies.
- 21 July 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (14) , e049636
Comparison of Outcomes of Leadless Versus Transvenous Pacemakers Following Tricuspid Valve Surgery
Background: Transvenous pacemaker implantation after tricuspid valve surgery may cause adverse outcomes due to lead–valve interactions. Although leadless pacemakers may mitigate these risks, empirical data remain limited. Methods: We compared outcomes of leadless versus transvenous pacemakers following tricuspid surgery using a target trial emulation framework. We analyzed Medicare beneficiaries aged ≥65 years who underwent tricuspid valve surgery and received a pacemaker during the index admission between 2017 and 2021, using propensity score matching weight analysis to control for confounders. Primary outcomes were in‐hospital death and 2‐year heart failure hospitalization. Secondary outcomes included 2‐year death. Results: We included 185 and 1336 patients in the leadless and transvenous groups, respectively. Use of leadless pacemakers increased from 6.3% in 2017 to 17.5% in 2021. Leadless pacemaker recipients more often underwent tricuspid valve replacement (29.2% versus 8.5%) while concomitant mitral surgery was less common (69.2% versus 86.8%). After adjustment, we found no evidence that in‐hospital death (adjusted odds ratio, 1.82 [95% CI, 0.65–5.13] for leadless) and 2‐year heart failure hospitalizations (subdistribution hazard ratio [HR], 0.88 [95% CI, 0.60–1.30] for leadless) differed between the 2 groups. We also found no evidence that 2‐year death (adjusted HR, 1.04 [95% CI, 0.69–1.57] for leadless) differed between groups. Conclusions: No statistically significant differences were detected between leadless versus transvenous pacemaker implantations after tricuspid valve surgery. However, CIs were wide, and a clinically meaningful difference in either direction cannot be excluded. The study may therefore be underpowered, and the absence of echocardiographic data limits assessment of tricuspid regurgitation, warranting prospective studies.
- 7 July 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (13) , e050652
Outcomes of Percutaneous and Surgical Interventions of Right‐Sided Heart Masses in Older Patients: A Nationwide Comparative Study
Background: Percutaneous aspiration thrombectomy is increasingly used as an alternative to surgery for right‐sided heart masses, but nationwide data are limited. Methods: We analyzed Medicare fee‐for‐service beneficiaries aged ≥65 years who underwent percutaneous or surgical removal of right‐sided heart masses from 2016 to 2021. We examined the temporal change in the number of percutaneous and surgical cases. The association between procedural types and patient characteristics was assessed using a multivariable logistic regression analysis. The primary outcomes were in‐hospital and 2‐year death. Given baseline differences between groups, we reported overall outcomes from the unadjusted cohort and comparative outcomes after adjustment using propensity score matching. Results: A total of 831 patients were included (447 percutaneous, 384 surgical), with the proportion of percutaneous cases increasing from 45.8% in 2016 to 65.0% in 2021. Patients with thrombosis (adjusted odds ratio, 3.42 [95% CI, 2.14–5.46]) and infective endocarditis (adjusted odds ratio, 10.08 [95% CI, 5.39–18.85]) were more often treated with percutaneous interventions. In‐hospital and 2‐year death in the percutaneous group were 11.0% and 43.0%, respectively. In the surgery group, those were 21.1% and 42.9%, respectively. Propensity score matching yielded 221 pairs. In the matched cohort, in‐hospital death remained lower with the percutaneous group (10.4% versus 19.5%; P =0.01), while 2‐year death was similar (hazard ratio, 1.00 [95% CI, 0.74–1.34]). Conclusions: This study from a national database demonstrated that percutaneous intervention for right‐sided heart masses has become the predominant strategy compared with surgery. Further trials are required to compare efficacy and safety between these interventions.
- 7 July 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (13) , e050652
Outcomes of Percutaneous and Surgical Interventions of Right‐Sided Heart Masses in Older Patients: A Nationwide Comparative Study
Background: Percutaneous aspiration thrombectomy is increasingly used as an alternative to surgery for right‐sided heart masses, but nationwide data are limited. Methods: We analyzed Medicare fee‐for‐service beneficiaries aged ≥65 years who underwent percutaneous or surgical removal of right‐sided heart masses from 2016 to 2021. We examined the temporal change in the number of percutaneous and surgical cases. The association between procedural types and patient characteristics was assessed using a multivariable logistic regression analysis. The primary outcomes were in‐hospital and 2‐year death. Given baseline differences between groups, we reported overall outcomes from the unadjusted cohort and comparative outcomes after adjustment using propensity score matching. Results: A total of 831 patients were included (447 percutaneous, 384 surgical), with the proportion of percutaneous cases increasing from 45.8% in 2016 to 65.0% in 2021. Patients with thrombosis (adjusted odds ratio, 3.42 [95% CI, 2.14–5.46]) and infective endocarditis (adjusted odds ratio, 10.08 [95% CI, 5.39–18.85]) were more often treated with percutaneous interventions. In‐hospital and 2‐year death in the percutaneous group were 11.0% and 43.0%, respectively. In the surgery group, those were 21.1% and 42.9%, respectively. Propensity score matching yielded 221 pairs. In the matched cohort, in‐hospital death remained lower with the percutaneous group (10.4% versus 19.5%; P =0.01), while 2‐year death was similar (hazard ratio, 1.00 [95% CI, 0.74–1.34]). Conclusions: This study from a national database demonstrated that percutaneous intervention for right‐sided heart masses has become the predominant strategy compared with surgery. Further trials are required to compare efficacy and safety between these interventions.
- 22 June 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (12) , 1595-1603
UNICORN During Transcatheter Aortic Valve Replacement in Native and Bioprosthetic Aortic Valves
- 22 June 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (12) , 1595-1603
UNICORN During Transcatheter Aortic Valve Replacement in Native and Bioprosthetic Aortic Valves
- Open Access
- 7 April 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (7) , e046367
Comparison of Intravascular Imaging–, Physiology‐, or Angiography‐Guided Approaches for Percutaneous Coronary Intervention: A Systematic Review and Network Meta‐Analysis
Background: Despite current guidelines recommending physiology‐ and intravascular imaging–guided percutaneous coronary intervention (PCI) in specific lesion subsets, angiography‐guided PCI remains common in practice. The comparative effectiveness of these strategies remains uncertain. We aimed to compare clinical outcomes of PCI guided by intravascular imaging or physiological assessment versus conventional angiography. Methods: We conducted a systematic review and network meta‐analysis of randomized controlled trials, searching PubMed and EMBASE up to May 31, 2025. Eligible studies compared at least 2 of the following 6 guidance modalities in PCI: angiography, intravascular ultrasound (IVUS), optical coherence tomography/optical frequency domain imaging, fractional flow reserve, angiography‐derived fractional flow reserve, and instantaneous wave‐free ratio. The primary outcome was trial‐defined major adverse cardiovascular events (MACEs). Hazard ratios (HRs) with 95% CIs were pooled using a frequentist random‐effects network meta‐analysis. Subgroup analyses assessed clinical presentation and guidance objectives such as decision making and procedural optimization. Results: We identified 43 randomized controlled trials involving 39 291 patients. IVUS‐guided PCI (HR, 0.69 [95% CI, 0.60–0.79]), optical coherence tomography/optical frequency domain imaging‐guided PCI (HR, 0.75 [95% CI, 0.63–0.90]), and fractional flow reserve–guided PCI (HR, 0.81 [95% CI, 0.70–0.95]) were associated with a lower risk of MACEs compared with angiography‐guided PCI. Furthermore, IVUS‐guided PCI was associated with a lower risk of MACEs compared with instantaneous wave‐free ratio–guided PCI (HR, 0.74 [95% CI, 0.55–1.00]). IVUS‐guided PCI reduced the risk of MACE in both acute coronary syndrome and non‐acute coronary syndrome patients. Conclusions: IVUS‐ and optical coherence tomography/optical frequency domain imaging–guided PCI were superior to angiography‐guided PCI in reducing MACEs. Among the physiology‐based approaches, only fractional flow reserve showed a clear benefit.
- 7 April 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (7) , e046367
Open AccessComparison of Intravascular Imaging–, Physiology‐, or Angiography‐Guided Approaches for Percutaneous Coronary Intervention: A Systematic Review and Network Meta‐Analysis
Background: Despite current guidelines recommending physiology‐ and intravascular imaging–guided percutaneous coronary intervention (PCI) in specific lesion subsets, angiography‐guided PCI remains common in practice. The comparative effectiveness of these strategies remains uncertain. We aimed to compare clinical outcomes of PCI guided by intravascular imaging or physiological assessment versus conventional angiography. Methods: We conducted a systematic review and network meta‐analysis of randomized controlled trials, searching PubMed and EMBASE up to May 31, 2025. Eligible studies compared at least 2 of the following 6 guidance modalities in PCI: angiography, intravascular ultrasound (IVUS), optical coherence tomography/optical frequency domain imaging, fractional flow reserve, angiography‐derived fractional flow reserve, and instantaneous wave‐free ratio. The primary outcome was trial‐defined major adverse cardiovascular events (MACEs). Hazard ratios (HRs) with 95% CIs were pooled using a frequentist random‐effects network meta‐analysis. Subgroup analyses assessed clinical presentation and guidance objectives such as decision making and procedural optimization. Results: We identified 43 randomized controlled trials involving 39 291 patients. IVUS‐guided PCI (HR, 0.69 [95% CI, 0.60–0.79]), optical coherence tomography/optical frequency domain imaging‐guided PCI (HR, 0.75 [95% CI, 0.63–0.90]), and fractional flow reserve–guided PCI (HR, 0.81 [95% CI, 0.70–0.95]) were associated with a lower risk of MACEs compared with angiography‐guided PCI. Furthermore, IVUS‐guided PCI was associated with a lower risk of MACEs compared with instantaneous wave‐free ratio–guided PCI (HR, 0.74 [95% CI, 0.55–1.00]). IVUS‐guided PCI reduced the risk of MACE in both acute coronary syndrome and non‐acute coronary syndrome patients. Conclusions: IVUS‐ and optical coherence tomography/optical frequency domain imaging–guided PCI were superior to angiography‐guided PCI in reducing MACEs. Among the physiology‐based approaches, only fractional flow reserve showed a clear benefit.
- Open Access
- 3 July 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (8) , 101900
Impact of Sex and Age on Trends of Mortality From Infective Endocarditis in High-Income Countries
- 3 July 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (8) , 101900
Open AccessImpact of Sex and Age on Trends of Mortality From Infective Endocarditis in High-Income Countries
- Open Access
- 28 May 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (10) , 101770
Long-Term Outcomes Following Catheter-Based Therapies in Older Adults With Acute Pulmonary Embolism
- 28 May 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (10) , 101770
Open AccessLong-Term Outcomes Following Catheter-Based Therapies in Older Adults With Acute Pulmonary Embolism
- Open Access
- 24 March 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (5) , 101706
Mechanical Thrombectomy vs Catheter-Directed Thrombolysis for High-Risk Pulmonary Embolism
- 24 March 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (5) , 101706
Open AccessMechanical Thrombectomy vs Catheter-Directed Thrombolysis for High-Risk Pulmonary Embolism
- 10 February 2025
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 18 (3) , 311-321
Transapical Transcatheter Mitral Valve Replacement After Failed Transcatheter Edge-to-Edge Repair
- 10 February 2025
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 18 (3) , 311-321
Transapical Transcatheter Mitral Valve Replacement After Failed Transcatheter Edge-to-Edge Repair